Approval was expected but it came 3 months ahead of the PDUFA date.
Given the apparent synergies, at least preclinically, with 0GX-011 for which OGXI presented evidence at ASCO 2011, it's conceivable that Teva would now fund a combination trial. I think it's more likely that they'll wait until MDVN shows efficacy in the larger pre-chemo setting. By then they may have results from SYNERGY, and that will probably be the main factor determining whether they want to initiate additional new trials of 011.
BTW, Yahoo in its never-ending quest to improve the user experience, would not let me post a link to a Reuters article on the approval of MDVN's drug. This is supposedly to prevent spam. I guess I will provide them feedback indicating that ideas like this are not going to turn Yahoo around.